Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc.'s increased investment in research and development, rising from $4.5 million to $7.4 million, reflects a strategic focus on advancing its clinical programs and infrastructure, indicating a commitment to innovation in fibroblast-based therapies. Preclinical findings suggest that the lead product candidate, CYWC628, shows promising results in enhancing tissue regeneration and modulating inflammatory responses, which could address significant unmet medical needs in wound healing and chronic diseases. Furthermore, the company has successfully strengthened its capital structure with $7.2 million in direct offerings and eliminated all outstanding debt, resulting in a cash position of $4.9 million, positioning it well for future clinical progress and financing opportunities.

Bears say

FibroBiologics faces significant challenges following a recent reverse stock split, which often leads to disruptions in the existing shareholder base, increased selling pressure, and devaluation of investor confidence. The downgrade from a Buy to a Hold status suggests that the company will likely experience prolonged investor sentiment and liquidity issues that may hinder financial recovery for an extended period. Additionally, while the global burn care market presents substantial opportunities, the impact of the reverse split on stock liquidity and investor sentiment raises concerns about the company's near-term financial stability and valuation potential.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.